Sanofi has joined Eli Lilly and Novo Nordisk as the last of the 3 biggest suppliers of insulin in the US to announce price cuts and caps for out-of-pocket costs in insulin. The French drugmaker announced Thursday that it will be capping the out-of-pocket costs of its most popular insulin, Lantus to!-->…
Read More...